Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Familial AD-derived neuroprogenitor cells show pronounced mitochondrial metabolism disruption

Marina Trombetta Lima, PhD, University of Groningen, Groningen, The Netherlands, talks on an investigation of mitochondrial metabolism alterations in Alzheimer’s disease (AD). Neuroprogenitor cells (NPCs) were generated using induced pluripotent stem cells (iPSCs) from patients with familial AD, isogenic controls, and healthy subjects. Measures of metabolic activity (mitochondrial respiration, glycolytic rate, and metabolic substrate usage) and expression of metabolic pathway proteins were assessed to determine the presence of mitochondrial metabolism disruption. It was demonstrated that mitochondrial metabolism was already significantly impaired in familial AD-derived NPCs, suggesting these changes could be a valuable target for early intervention. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.